Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Alexandre SeprianoAndreas KerschbaumerSytske Anne BergstraJosef S SmolenDésirée Mfm van der HeijdeRoberto CaporaliChristopher J EdwardsPatrick VerschuerenSavia de SouzaJanet E PopeTsutomu TakeuchiKimmie L HyrichKevin L WinthropDaniel AletahaTanja Alexandra StammJohan A F KoekkoekRobert B M LandewePublished in: Annals of the rheumatic diseases (2022)
The safety profile of bDMARDs was further demonstrated. Whether the difference in incidence of malignancies, MACE and VTE between tofacitinib and TNFi applies to other JAKi needs further evaluation.